Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal dexmedetomidine for pain reduction during ROP eye examinations in preterm infants
MOH_2023-10-23_012955Phase 3Not yet recruiting
- Sponsor
- ד"ר שגיא ניסימוב
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in retinopathy of prematurity (ROP) (2 arms), sponsored by ד"ר שגיא ניסימוב. Primary endpoint: Pain during eye examination. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on MOH_2023-10-23_012955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-23_012955.